1. S-1 chemotherapy improves survival rate in pancreatic cancer patients.
2. Nab-paclitaxel earned approval for use in pancreatic cancer treatment.
3. Colorectal cancer with NRAS mutations is unlikely to benefit from panitumumab.
4. Capecitabine and bevacizumab are standar maintenance therapy in colorectal cancer.
5. Octreotide LA prolongs survival in midgut neuroendocrine tumors.
More Articles on Gastroenterology:
6 Things to Know About Infliximab as Ulcerative Colitis Treatment
5 Recent GI-Driven Center Openings & Plans
The Promise of Stem Cell Treatment for Crohn’s Disease & Ulcerative Colitis: Q&A With Dr. William Katkov
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
